Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, 2025. Despite a significant drop in net profit, revenue and EBITDA have grown. Increased biosimilar market share and strategic approvals are expected to drive future growth.
Nifty must defend 23,800 level to retain bullish undertone
Stocks offering short-term trading opportunities include Bharti Airtel, Godrej Consumer, Grasim, Havells, ICICI Bank, Marico, Sun Pharma, Tata Consumer, Navin Fluorine, Persistent Systems, Aarti Industries,
April 28, 2025